• The "New" Prostate Cancer InfoLink has been developed to become a primary source of accurate, current, and topical information about prostate cancer for patients and their families.
  • This web site is a service of Prostate Cancer International.

    pcai_cmyk

  • Other PCI web sites

  • The "New" Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services.

    News and information provided on this site should not be used for diagnosing or treating any health problem or disease.

    The "New" Prostate Cancer InfoLink is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.

    • Perspective Confidentiality Disclosure Reliability Courtesy

First use of NOTES for radical prostatectomy

Natural orifice transluminal endoscopic surgery or NOTES refers to the conduct of minimally invasive surgery through natural orifices (like the mouth or the vagina or the nose). … READ MORE …

New trial of VTP for localized prostate cancer opens at five US centers

A media release from New York University Langone Medical Center, issued yesterday, has announced the initiation of a multi-center, Phase I/II clinical trial of vascular-targeted photodynamic therapy (VTP) in men with localized prostate cancer. … READ MORE …

What’s “bipolar” androgen therapy? How does it work?

Traditional forms of hormone therapy for prostate cancer are based on the idea that you reduce testosterone levels as low as you can so as to stop the ability of testosterone and its metabolites (e.g., dihydrotestosterone) to stimulate growth of prostatic tissues — including prostate cancer cells. … READ MORE …

5-year brachytherapy outcomes vs. predicted surgical outcomes

As an adjunct to the 12-year outcome data provided in the immediately preceding report come data from Canada that compare actual 5-year brachytherapy outcome data to predicted 5-year surgical outcome data for the same patients. … READ MORE …

12-year follow-up data on first-line brachytherapy for localized prostate cancer

The long-term data on outcomes after first-line treatment with brachytherapy for localized prostate cancer are becoming increasingly compelling, and studies have also suggested strongly that quality of life data are better after brachytherapy than after other forms of treatment. … READ MORE …

Diagnosis and management of low-risk disease with a PSA < 4.0

There is a good deal of media noise today about a newly published study in Archives of Internal Medicine. The study addresses the “risk profiles and treatment patterns” of US prostate cancer patients diagnosed with a PSA of ≤ 4.0 ng/ml.” … READ MORE …

US research team wins contract to study comparative effectiveness of prostate cancer treatments

According to a media release issued yesterday by the University of North Carolina Lineberger Cancer Center, researchers at this institution have been  awarded the first contract we are aware of  ”to conduct comparative effectiveness research comparing different management strategies for localized prostate cancer.” … READ MORE …

What is the DoD PCRP? And why does it matter?

DoD PCRP stands for the Congressionally mandated Department of Defense Prostate Cancer Research Program — and it is the only US government-sponsored initiative that dedicates funding specifically to prostate cancer research. (Similar DoD cancer programs provide dedicated funding for research into breast, lung, colon, and ovarian cancers.) … READ MORE …

Prostate cancer news reports: Monday, July 26, 2010

There are several interesting new publications worth commenting on this morning — all in the evolving research field as opposed to current clinical practice:

  • Angiogenic effect of a specific statin on prostate cancer development
  • Synergistic impact of calcitriol on cryotherapy
  • Hybrid imaging techniques and prostate cancer
  • GTI-2040 in treatment of CRPC … READ MORE …

You can keep drinking the java (maybe)

The conclusion of a meta-analysis of data from 12 prior studies suggests that drinking coffee has no significant impact on risk for prostate cancer. This news will no doubt come as a great relief to the good people at Starbucks! … READ MORE …

Genetic testing for prostate cancer “in the real world”

Over the past few months, the US Food and Drug Administration (FDA) has issued a slew of letters to companies marketing tests designed to provide consumers with information about their genetic profile and their risks for certain types of disease. … READ MORE …

Overall survival of men diagnosed with advanced disease: an update

On July 8, we wrote about the long-term survival of patients initially diagnosed with metastatic forms of prostate cancer — and a new article on this subject has just appeared in the Journal of Urology. … READ MORE …

Time to give The Daily Mail the finger!

Sometimes it is difficult to decide who to be more irritated at … the researchers who publish highly dubious data, the PR people who send out the breathless press releases touting the highly dubious data, or the media that actually publish these data as if they are correct and/or important. … READ MORE …

A “standardized,” on-line calculator for PSADT

PSA doubling time or PSADT is a valuable prognostic factor in assessing the need for second- or even third-line treatment in men with biochemical progression of prostate cancer. … READ MORE …

Suspension of ADT in patients with a long-term, stable response to treatment

There has long been discussion about the theoretical possibility of suspending androgen deprivation therapy (ADT) in men with a long-term, stable response to this form of hormonal therapy. However, there have been few long-term data reported on responses to this strategy. … READ MORE …